Abstract
399P Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have